Go to content

Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Levo floxacin (Quinsair®) for the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa

    The National Health Care Institute carried out a marginal assessment of the medicine levofloxacin (Quinsair®), whereby they came ...

    Report | 03-05-2016

  2. Early Intensive Neurorehabilitation of adults with unresponsive wakefulness syndrome or a prolonged minimally conscious state

    This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.

    Report | 29-03-2016

  3. Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

    The National Health Care Institute has approved a pharmacotherapeutic report for the medicine safinamide (Xadago®). They reached ...

    Report | 21-03-2016

  4. Onabotulinum toxin A 100 U in cases of idiopathic overactive bladder

    The National Health Care Institute concluded that treatment with onabotulin toxin A 100 U does comply with the established ...

    Report | 25-02-2016

  5. Ivermectin (Soolantra®) by moderate to severe papulopustulous rosacea

    The National Health Care Institute advises the Minister of Public Health, Welfare and Sport to include ivermectin (Soolantra®) in ...

    Report | 22-02-2016

  6. Eltrombopag (Revolade®) in cases of severe aplastic anaemia

    The National Health Care Institute has approved a pharmacotherapeutic report for the medicine eltrombopag (Revolade®) in cases of ...

    Report | 22-02-2016

  7. Health care in the Netherlands

    The philosophy underpinning the Dutch health care system is based on several more or less universal principles: access to care ...

    Publication | 31-01-2016

  8. Tolvaptan (Jinarc) by cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD)

    Based on the criteria for mutual replaceability, tolvaptan is not eligible for placing on List 1A of the GVS. Nor is tolvaptan ...

    Report | 14-12-2015

  9. Cost-effectiveness in practice

    Cost-effectiveness is one criterion that helps us to make responsible choices. It gives us insight into how much “value we are ...

    Report | 16-06-2015

  10. Zinnige Zorg - Systematic Analysis of neoplasms

    The National Health Care Institute published this report within the context of a systematic examination of the insured package.1 ...

    Report | 16-04-2015

Go to